User Settings
Open AccessArticle10.1056/nejmoa1506223

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

Sri Rezeki Hadinegoro,José Luis Arredondo-Garcı́a,Maria Rosario Capeding,Carmen Deseda,Tawee Chotpitayasunondh,Reynaldo Dietze+18 more-2015-07-27-New England Journal of Medicine
1.1KPDF

TL;DRAbstract

Although the unexplained higher incidence of hospitalization for dengue in year 3 among children younger than 9 years of age needs to be carefully monitored during long-term follow-up, the risk among children 2 to 16 years of age was lower in the vaccine group than in the control group. (Funded by Sanofi Pasteur; ClinicalTrials.gov numbers, NCT00842530, NCT01983553, NCT01373281, and NCT01374516.).

Chat with Paper

AI Agents for this Paper

Although the unexplained higher incidence of hospitalization for dengue in year 3 among children younger than 9 years of age needs to be carefully monitored during long-term follow-up, the risk among children 2 to 16 years of age was lower in the vaccine group than in the control group. (Funded by Sanofi Pasteur; ClinicalTrials.gov numbers, NCT00842530, NCT01983553, NCT01373281, and NCT01374516.).

Keywords

MedicineDengue feverDengue vaccineConfidence intervalIncidence (geometry)Clinical trialInterim analysisVaccine efficacy

Chat

Click to start Chat